What You Must Know About Cystic Fibrosis Drug CTP-656
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
Vertex Pharmaceuticals (VRTX) - Get Report is acquiring a longer-acting version of its Kalydeco cystic fibrosis drug from from Concert Pharmaceuticals (CNCE) - Get Report . Although both drugs are essentially the same, CTP-656 poses the possibility for a once-daily pill.
READ THE FULL STORY HERE: Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma
This article was written by a staff member of TheStreet.
